Previous studies have reported a 45% risk of eyes with neovascular age-related macular degeneration (nAMD) developing subretinal fibrosis while receiving anti-vascular endothelial growth factor (anti-VEGF) therapy for 2 years (7). This evidence concerns the gene VEGFA and wet macular degeneration.